Valeant CEO expects sharp rise in Asia revenue by 2020

May 19, 2015 5:04 PM

10 5

MONTREAL May 19 Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020, Chief Executive Michael Pearson said on Tuesday.

Montreal-based Valeant is Canada's largest pharmaceutical company, with top-selling products including heart treatment Isuprel and anti-depressant Wellbutrin. It has been a serial acquirer, with deals lifting its revenue to more than $8 billion in 2014.

Also read: BAT heaps $47 bln of peer pressure on Reynolds

Read more

To category page